Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $32.25.

A number of analysts have recently weighed in on DTIL shares. Wall Street Zen cut shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Oppenheimer assumed coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday, August 5th.

Precision BioSciences Trading Up 0.3%

Shares of NASDAQ DTIL opened at $6.63 on Thursday. Precision BioSciences has a 1-year low of $3.53 and a 1-year high of $9.62. The business has a fifty day moving average price of $7.67 and a 200 day moving average price of $7.08. The stock has a market capitalization of $182.99 million, a P/E ratio of -2.37 and a beta of 1.24. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82.

Precision BioSciences (NASDAQ:DTIL) last posted its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 72.52%. Equities research analysts expect that Precision BioSciences will post -3.33 EPS for the current fiscal year.

Institutional Trading of Precision BioSciences

Several hedge funds and other institutional investors have recently made changes to their positions in DTIL. Octagon Capital Advisors LP boosted its position in shares of Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after purchasing an additional 318,737 shares in the last quarter. Empery Asset Management LP acquired a new stake in Precision BioSciences in the fourth quarter worth about $9,130,000. Affinity Asset Advisors LLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $3,289,000. Corient Private Wealth LP increased its holdings in shares of Precision BioSciences by 70.4% during the second quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after acquiring an additional 101,206 shares in the last quarter. Finally, Squarepoint Ops LLC increased its holdings in shares of Precision BioSciences by 212.7% during the second quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after acquiring an additional 93,258 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile